Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: A systematic analysis of international guidelines and recommendations

Leukemia and Lymphoma

Volumn 52, Issue 3, 2011, Pages 444-457

  Hübel, Kai ^a   Weingart, Olaf ^a   Naumann, Frauke ^a   Bohlius, Julia ^b   Fresen, Maximilian M ^a   Engert, Andreas ^a   Wheatley, Keith ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

acute myelogenous leukemia; Allogeneic transplant; guidelines

Indexed keywords

AMSACRINE; ANTHRACYCLINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HLA ANTIGEN; IDARUBICIN; MITOXANTRONE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOGENETICS; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; GRAFT VERSUS HOST REACTION; HUMAN; MULTIPLE CYCLE TREATMENT; ORGAN DONOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; REMISSION; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; CONTROLLED CLINICAL TRIALS AS TOPIC; DONOR SELECTION; HEALTH PLANNING GUIDELINES; HUMANS; INTERNATIONALITY; LEUKEMIA, MYELOID, ACUTE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79951714520     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546918     Document Type: Article

References (50)

1. Ries LAG, Melbert D, Krapchoa M, Maiotto A, Miller BA, Feuer EJ. SEER Cancer Statistics Review 1975-2004. Bethesda, MD: National Cancer Institute, Surveillance Epidemiology and End Results (SEER); 2007.
2. Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001;98:3500.
3. Biggs JC, Horowitz MM, Gale RP et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090-1093.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American- British (FAB) co-operative group. Br J Haematol 1976;33:451-458.
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
6. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials. Blood 2005;106:3658-3665. (Pubitemid 41609208)
7. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
8. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006;135:450-474. (Pubitemid 44596187)
9. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-223.
10. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400. (Pubitemid 34994639)
11. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-1656. (Pubitemid 28550689)
12. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20:1673-1682. (Pubitemid 44590957)
13. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219-234.
14. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009;43:275-291.
15. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008;93:594-600.
16. Lee SJ, Joffe S, Artz AS, et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008;26:2162-2170.
17. Miura Y, Yamaguchi T, Azuma T, et al. Regional differences exist in allogeneic stem cell transplantation rates for acute leukemia. Int J Hematol 2008;87:236-238.
18. ASBMT. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in adults. Biol Blood Marrow Transplant 2008;14:135-136.
19. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2008;14: 137-180.
20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Acute myeloid leukemia [V.2.2010]. Jenkintown, PA: NCCN; 2010.
21. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-a statistician's view. Br J Haematol 2002;118:351-356. (Pubitemid 34994635)
22. Wheatley K, Gray R. Commentary: Mendelian randomization- an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004;33:15-17. (Pubitemid 38500148)
23. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol 1998;102:1344-1353. (Pubitemid 28435225)
24. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003;102:1232-1240. (Pubitemid 36988027)
25. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997;90:2978-2986. (Pubitemid 27444191)
26. Jourdan E, Boiron JM, Dastugue N, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 2005;23:7676-7684.
27. Breems DA, Boogaerts MA, Dekker AW, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 2005;128:59-65.
28. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969-1978. (Pubitemid 46211376)
29. Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-3506. (Pubitemid 27527723)
30. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-752. (Pubitemid 37010778)
31. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109:3658-3666.
32. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301:2349-2361.
33. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103:1652-1658. (Pubitemid 40490026)
34. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476-479. (Pubitemid 30142875)
35. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-1099. (Pubitemid 44154650)
36. Laane E, Derolf AR, Bjorklund E, et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006;91:833-836. (Pubitemid 44014555)
37. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542. (Pubitemid 39564424)
38. Mielcarek M, Storb R. Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev 2003;29:283-290. (Pubitemid 37069658)
39. Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005;19:916-920. (Pubitemid 40862000)
40. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:1395-1400.
41. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304-2312. (Pubitemid 41748028)
42. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007;110:4606-4613. (Pubitemid 351377830)
43. Ruggeri A, Ciceri F, Gluckman E, Labopin M, Rocha V. Alternative donors hematopoietic stem cells transplantations for adults with acute myeloid leukemia: umbilical cord blood or haploidentical donors? Best Pract Res Clin Haematol 2010;23:207-216.
44. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 2007;86:311-327. (Pubitemid 46477295)
45. Haferlach T, Schnittger S, Kern W, Hiddemann W, Schoch C. Genetic classification of acute myeloid leukemia (AML). Ann Hematol 2004;83(Suppl. 1):S97-S100.
46. Tallman MS, Dewald GW, Gandham S, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007;110:409-417. (Pubitemid 47026863)
47. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918. (Pubitemid 351620111)
48. Barry EV, Clark JJ, Cools J, Roesel J, Gilliland DG. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood 2007;110:4476-4479. (Pubitemid 351377814)
49. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
50. Fey M, Dreyling M. Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl. 2):ii58-ii59.